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enabled by digital photon counting PET/CT technology
K. Binzel1, A. Adelaja1, C. L. Wright1, D. Scharre2, J. Zhang1, M. V. Knopp1
1Wright Center of Innovation in Biomedical Imaging, Department of
Radiology, The Ohio State University Wexner Medical Center, Columbus,
OH, USA; 2Department of Neurology, The Ohio State University Wexner
Medical Center, Columbus, OH, USA
Correspondence: K. Binzel
EJNMMI Research 2018, 8(Suppl 1):OP01
Aim: To demonstrate the clinical capability of ultra-fast whole body
PET acquisition enabled by digital photon counting PET (dPET) and
to assess and compare its diagnostic and quantitative characteristics
to current clinical PET acquisition.
Methods: Twenty-five patients scheduled for FDG whole body PET/
CT were imaged using three separate acquisitions as part of intra-
individual comparison study with a pre-commercial release dPET/CT
(Vereos) and cPET/CT (Gemini, Philips, Cleveland). Standard cPET
imaging was performed at ~75 min p.i. of ~ 450 MBq FDG with in-
vestigational dPET imaged at ~55 min p.i. The first dPET acquisition
was performed using 90s/bed position, immediately followed by a
9s/bed position.
Acquisition which lead to average table times of ~15 and ~2 min.
These were compared with standard-of-care 90s/bed position cPET.
The 9s/bed dPET listmode data were reconstructed using a previ-
ously optimized methodology. All other aspects of image acquisition
were kept identical. Three blinded reviewers evaluated the data sets
regarding visual characteristics, diagnostic confidence and semi-
quantitative readouts.
Results: Visual assessment scores were significantly higher for 90s/bed
dPET whole body (p<0.01) with no difference between 9s/bed dPET
and 90s/bed cPET. Quantitatively, the 9s/bed dPET images presented
slightly increased background noise, however there was no significant
impact on diagnostic confidence or SUV measures of FDG-avid lesions.
Conclusion: Next generation digital photon counting PET detector
technology enables a new capability of Ultra-Fast (~2min) wholebody
acquisition with comparable diagnostic confidence and quantitative
precision to current generation cPET acquisitions taking 10 times lon-
ger. This allows for new PET workflow concepts, improved patient
comfort, minimized patient motion and whole-body pseudo-dynamic
imaging of tracer uptake.
Reference
1. Wright CL, Binzel K, Zhang J, Knopp MV. Advanced Functional Tumor Imaging
and Precision Nuclear Medicine Enabled by Digital PET Technologies. Contrast
Media & Molecular Imaging. 2017;2017:5260305. https://doi.org/10.1155/2017/
5260305.© The Author(s). 2018 Open Access This article
International License (http://creativecommons.o
reproduction in any medium, provided you giv
the Creative Commons license, and indicate ifOP02
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Aim: Detection of the extent of local recurrence and of
metastases in biochemical recurrence (BCR) of prostate cancer fa-
cilitates selection of appropriate treatment. The FALCON trial
(NCT02578940) assessed the impact of 18F-fluciclovine PET/CT on
the clinical management of men with BCR of prostate cancer
following initial radical therapy.
Methods: Men being considered for curative-intent salvage ther-
apy following first BCR were recruited at 6 UK sites. Management
plans were documented prior to and following 18F-fluciclovine
PET/CT imaging. Post-scan changes to treatment modality such as
salvage radiotherapy [RT] to systemic therapy were classed as
‘major’, while changes within a modality (e.g. modified RT fields)
were classed as ‘other’. A pre-planned interim analysis of the first
85 patients was conducted; recruitment was to be stopped for
efficacy if the number of treatment changes was > 45 (52.9%;
97.5% CI: 40.3–62.3%), or for futility if ≤ 8 (9.4%, 97.5% CI: 3.6–
18.9%).
Results: The 85 enrolled patients were a mean 4.8 y post-initial diag-
nosis, with a median age of 67 y and median PSA of 0.63ng/mL.
Twelve (14.1%) had a Gleason score ≤ 6, 60 (70.6%) had a
score of 7 and 13 (15.3%) had a score ≥ 8. Most (56; 65.9%)
had previously undergone radical prostatectomy (RP), with 27
having received RT (± other therapy). The majority of those
imaged (52; 61.2%) had a change in management (CIM) post-
scan (see Table 1). Recruitment was subsequently stop as the
pre-specified condition defining overwhelming efficacy was
met.
Conclusion: This prospective trial shows 18F-fluciclovine PET/CT
has substantial impact on clinical decisions for men with a
first BCR of prostate cancer after curative-intent primary
therapy.is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Table 1 (abstract OP02). See text for description
Patients N = 85




Pelvic lymph nodes 12/85 (14.1)
Bone 9/85 (10.6)
CIM: n (%) 52/85 (61.2)
Prior RP 24/52 (46.2)
Positive 18F-fluciclovine scan 41/52 (78.8)
Major CIM: n (%) 31/52 (59.6)
Salvage therapy to watchful waiting 13/52 (25.0)
Salvage therapy to systemic therapy 18/52 (34.6)
Other CIM: n (%) 21/52 (40.4)
Modified RT field 21/52 (40.4)
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Aim: L-[S-methyl- 11C]methionine (MET) PET is a highly sensitive and
established method for glioma imaging. Little is known about gender
specific aspects of glioma with respect to imaging characteristics.
The aim of this study was to assess gender specific differences in dis-
tribution, localization as well as in diagnosis by using MET PET of
newly diagnosed gliomas.
Methods: 160 glioma patients (45% female, mean age: 45, range 18 -
84 yrs.) were retrospectively analyzed. Gender specific differences
based on clinical presentation at the time of the diagnosis, visual
and semi-quantitative evaluation by means of tumor to background
(T/N) ratio in pre-surgical MET PET, the isocitrate dehydrogenase 1-
R132H mutational status (IDH1-R132H), and survival using Kaplan-
Meier estimates and a Cox proportional hazard model were
determined.
Results: There were no significant differences regarding clinical
symptoms, tumor size, histology, and IDH1-R132H mutations be-
tween male and female patients at the time of diagnosis. Neverthe-
less, statistically significant differences were found for the surgical
approach (tumor resection, open biopsy and stereotactic biopsy) as
well as for visual PET analysis (focal, focal-areal, multifocal-areal, areal,
and negative) between male and female studied patients (P< 0.01).
The T/N ratio was significantly higher in male than in female patients
(3.0 ± 1.5 vs. 2.5 ± 1.3, P= 0.03). Additionally, in comparison to female
patients, male patients showed a higher number of occipital tumors
(P= 0.02) and significantly lower median overall survival rate (76 vs.
112 months, P= 0.02).
Conclusion: Results of the study demonstrated gender specific differ-
ences in the localization of the tumor, MET PET analysis as well as in
the surgical approaches and survival rate in patients with gliomas.
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EJNMMI Research 2018, 8(Suppl 1):5 Page 3 of 12Aim: Targeted radioembolization therapy with intra-arterially admin-
istered Yttrium-90 microspheres is routinely used for patients with
unresectable hepatic malignancies and metastases. There remains an
unmet clinical need for accurate imaging based assessment of
Yttrium-90 (90Y) microsphere biodistribution in the lungs following
radioembolization. At present, pre-radioembolization planning uses
intra-arterial administration of 99mTc macroaggregated albumin
(MAA) followed by quantitative scintigraphy to detect and measure
extra-hepatic shunting from the liver to the lungs (i.e., lung shunt
fraction or LSF). During radioembolization, catheter-directed
microspheres may potentially pass through tumor-associated arterio-
venous shunts and then become deposited within the pulmonary
vasculature which can contribute to dose-dependent radiation pneu-
monitis [1]. Although scintigraphic bremsstrahlung imaging is
routinely used to qualitatively verify the microsphere distribution
within the treated liver, its utility in quantitatively assessing post-
radioembolization LSF is greatly limited. It has been demonstrated
that conventional PET imaging of the annihilation radiation
generated by 90Y internal pair production can produce diagnostic
images which can be further analyzed quantitatively [2]. Recently,
digital photon counting PET/CT (dPET/CT) imaging for post-
radioembolization assessment of 90Y microsphere biodistribution in
the liver was demonstrated to be clinical feasible [3, 4]. Furthermore,
preliminary results with dPET/CT demonstrates its capability for
detecting discrete foci of ultra-low dose residual 90Y microspheres
within post-radioembolization delivery systems (5-272 MBq). The aim
of this study is to generate clinical feasibility data for dPET/CT esti-
mation of 90Y microsphere LSF following radioembolization and
compare it with the pre-therapy 99mTc MAA LSF.
Methods: Standard pre-therapy 99mTc MAA and post-therapy 90Y
bremsstrahlung scintigraphic and SPECT/CT imaging was performed
in 8 patients who underwent routine interventional radioemboliza-
tion with 90Y glass microspheres. As part of an ongoing clinical trial,
90Y dPET/CT imaging of the lungs and liver was performed in each
patient (4-50 h following radioembolization) using a total image ac-
quisition time of 21 min. Intra-individual comparison of pre/post
therapy SPECT/CT and post-therapy dPET/CT image quality, intrahe-
patic radioactivity distribution, pre-/post-therapy concordance, and
volumetric assessment of intrahepatic radioactivity was performed
using the Intellispace Portal workstation (Philips). The 99mTc MAA
LSF was calculated using planar scintigraphy with regions of interest
(ROI) placed around the lungs and liver on anterior and posterior pla-
nar imaging. Pre-therapy 99mTc MAA LSF was calculated using the
geometric mean of the anterior and posterior counts of the lungs
with respect to the anterior and posterior counts of the lungs plus
liver. Digital PET/CT assessment of post-therapy 90Y microsphere LSF
was performed using MIMVista (MIM Software). ROIs of the lungs and
liver were again generating using a region-grow technique combined
with thresholding. 90Y LSF with dPET/CT was calculated using the in-
tegral activity in the lungs with respect to the integral activity in the
lungs plus liver.
Results: All patients had evaluable pre-therapy 99mTc MAA, post-
therapy 90Y bremsstrahlung, and post-therapy 90Y dPET/CT images
for qualitative assessment of intrahepatic radioactivity distribution. In
all patients, 90Y dPET imaging enabled better image quality and
increased 90Y-to-background contrast which improved qualitative
and quantitative volumetric assessment of intrahepatic microsphere
distribution when compared with bremsstrahlung SPECT. Post-
therapy dPET/CT also improved assessment for concordance/discord-
ance with pre-therapy MAA SPECT/CT when compared with
bremsstrahlung SPECT/CT. Post-therapy 90Y bremsstrahlung SPECT
consistently overestimated liver treatment volumes when compared
with pre-therapy MAA SPECT and 90Y dPET. There were no instances
of significant shunting of 90Y microspheres outside of the liver. No
discrete foci of abnormally increased 90Y activity were detected in
the lungs and dPET/CT estimation of 90Y LSF was consistently less
than the pre-therapy MAA LSF.Conclusion: To date, no quantitative PET measurement of the 90Y
microsphere LSF following radioembolization has been reported and
no data are currently available comparing the pre-therapy MAA LSF
and the post-therapy 90Y microsphere LSF. One challenge is that
there is no reference standard for estimating the LSF other than pla-
nar scintigraphic imaging of the chest and abdomen following the
intra-arterial MAA administration. Given that 90Y microsphere dosage
is based upon the pre-therapy 99mTc MAA LSF and that MAA parti-
cles are more variable in size (e.g., 10-90 microns) than 90Y micro-
spheres (20-35 microns), quantitative estimation of the post-therapy
90Y microsphere LSF using dPET/CT approaches may have diagnostic
and therapeutic impact by identifying patients with smaller or larger
than anticipated LSFs. In particular, subsets of patients would be
identified on post-therapy 90Y PET imaging that may be eligible for
additional radioembolization therapy (i.e., patients with 50 Gy cumu-
lative lung dose). Routine estimates of 90Y dPET LSF would also
greatly increase our understanding of tumor-induced neovascularity
and the degree of vascular shunting in various liver malignancies/
metastases targeted by 90Y radioembolization therapy.
Research Support: This project was enabled by the Ohio Third
Frontier Awards (TECH 09-028, TECH 10-012, TECH 13-060), Wright
Center of Innovation in Biomedical Imaging Development Fund.
Philips Healthcare provided the investigational pre-commercial
release dPET/CT system. CLW is supported by American Cancer
Society, Radiological Society of North America, and National Cancer
Institute – Clinical Research Loan Repayment Program.
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Aim: The aim of our study was to measure the ED and organ doses
for conventional subtraction scintigraphy, dual-phase MIBI SPECT/CT
and FCH dual-phase PET/CT.
Methods: Twenty-five patients referred for parathyroid imaging with
a clinical indication of primary hyperparathyroidism underwent para-
thyroid subtraction scintigraphy and dual-phase SPECT/CT imaging
with the addition of FCH PET/CT. Radiation exposure was calculated
for administered activities of radiopharmaceuticals using ICRP
weighting factors and for CT exposure at hybrid imaging using dose-
length products and ImPACT CT Patient Dosimetry Calculator.
Results: The highest radiation exposure was caused by conventional
parathyroid subtraction scintigraphy (7.27 mSv), followed by dual-
phase MIBI SPECT/CT (6.81 mSv). The radiation exposure was lowest
for dual-phase FCH PET/CT imaging (2.86 mSv). The added CT im-
aging for both hybrid approaches did not cause significant additional
EJNMMI Research 2018, 8(Suppl 1):5 Page 4 of 12radiation exposure (1.41 mSv for MIBI SPECT/CT, additional 26.11 %
to overall exposure; 0.86 mSv for FCH PET/CT, additional 43.51 % to
overall exposure).
Conclusion: According to our results, emerging FCH PET/CT imaging
techniques lower radiation exposure to patients in comparison to
conventional scintigraphic imaging for HPG
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Aim: Tau deposition is one of the neuropathological hallmarks of
Alzheimer’s disease (AD). Among the different developed radio-
tracers, the 2-arylquinoline derivatives (S)-[18F]THK5117 and
[18F]THK5351 show high affinity for neurofibrillary tangles [1, 2]. In
vivo quantification of tau binding is usually performed by calculating
uptake ratios between tau-rich target regions and non-target regions
in the brain. However, kinetic modelling has also been proposed as
an alternative to determine tau binding. Whereas these radiotracers
have been investigated in different mouse AD models, kinetic model-
ling is precluded in mice by their small blood volume. Due to their
higher blood volume, rat models with tau pathology may thus offer
the possibility to perform arterial blood sampling and kinetic model-
ling. To determine the feasibility of this approach, we measured
blood pharmacokinetics and radiotracer metabolism in female and
male rats.Methods: Female and male rats (n=4-6) were cannulated via the fem-
oral artery for continuous blood sampling. Blood sampling was per-
formed every 5-6 sec for the first 3 min and then at 5, 10, 20, 30, 40,
50 and 60 min after (S)-[18F]THK5117 or [18F]THK5351 injection.
After collection of the 60 min blood sample, animals were sacrificed
and organs were excised. Blood from minute 5, 20 and 60 was proc-
essed to plasma. Radiolabelled metabolites in plasma, brain, liver and
urine were analyzed by radio-thin-layer chromatography (radio-TLC).
Results: Plasma pharmacokinetics and metabolism were significantly
different between female and male rats for both investigated
radiotracers. (S)-[18F]THK5117 plasma clearance was faster in female
(1.33±0.24 mL/h/kg BW) than in male (0.87±0.17 mL/h/kg BW) rats
(p=0.003). For (S)-[18F]THK5117, the percentage of unmetabolized
parent was different between both sexes (5 min: 63% (f) vs 78% (m),
p=0.02; 20 min: 43% (f) vs 23% (m), p<0.0001; 60 min: 32% (f) vs 9%
(m), p<0.00001). Similar observations were made for [18F]THK5351.
Plasma clearance was faster in female compared to male rats
(1.07±0.23 mL/h/kg BW vs 0.67±0.04 mL/h/kg BW, p=0.02) and the
percentage of radiolabelled metabolites in plasma was also different
(20 min: 50% (f) vs 19% (m), p=0.01; 60 min: 37% (f) vs 4% (m),
p<0.0001). In the liver, 13% (f) vs 6% (m) unchanged parent was mea-
sured for (S)-[18F]THK5117 and 16% (f) vs 3% (m) for [18F]THK5351. In
the brain, 91-96% and 84-90% of total radioactivity consisted of unme-
tabolized (S)-[18F]THK5117 and [18F]THK5351, respectively.
Conclusion: Our results show pronounced sex differences in blood
pharmacokinetics and metabolism of [18F]THK5117 and
[18F]THK5351 in rats. Female animals showed a faster plasma clear-
ance of both radiotracers. These results underline the importance of
investigating both sexes and also support the notion that individual
input functions are needed for kinetic modelling analyses.
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Aim: We present a new approach to solid phase peptide labeling on
a microfluidic system based on the PMMA matrix with the c18t sor-
bent. The chip allows for in-situ labelling at elevated temperatures
up to 100 °C. Labeling is performed in the three subsequent steps.
EJNMMI Research 2018, 8(Suppl 1):5 Page 5 of 12Methods: 1st step: The selected peptide precursor was loaded onto
the microfluidic chip activated with 2 ml of water and 2 ml of EtOH
and then flushed with 0.1 M MES mobile phase at pH 5.5. As a model
peptide we chose DOTA-TOC that was injected in a 500 μl volume
(12.5 μg) and deposited on the sorbent matrix (C18t, 20 mg in a vol-
ume of 100 μl).
2nd step: The microfluidic chip was heated up to 95 °C and a chosen
radiometal was injected into the system (64Cu, 300 MBq, 1 MBq/μl in
0.1 MES buffer). The free radiometal was eluted to waste, while the
chelated radiometal remained on the chip.
3rd step: The radiolabelled product was eluted from the system into
the organic phase (injection of 100 μl of EtOH).
Results: More than 90 % of the 64Cu activity was absorbed on
the chip. The radiolabelled product was then eluted with 100 μl
of EtOH in amount of 180 MBq, i.e. in the overall yield of 60 %
in ca 25 minutes. Radiochemical purity determined via HPLC was
found to be > 98 %.
Conclusion: We tested a newly designed microfluidic chip system
suitable for radiometal labellings. It was demonstrated on a particular
example of DOTA-TOC and 64Cu that the system allows for rapid
radiolabelling in three simple steps providing high radiochemical
purity product. The chip may be easily operated in GMP-compliant
mode and modified for various couples radiometal-precursor.
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Aim: The aim of this system is to simultaneously improve sensitiv-
ity and resolution with a major step compared to current state-
of-the art PET while maintaining a reasonable cost for the total
system. The first aim of this study is to show the potential of
high resolution monolithic LYSO scintillator with SiPM readout for
a compact Total Body (TB) PET design with only 3-4 times the
detector material of a current PET-CT scanner. The second aim of
this study is the design of a long axial TB-PET system and the
determination of its sensitivity gains for different types of objects.
The transverse diameter of the system is fixed at 65 cm (which
fits nearly all patients) as we expect that the whole bore can be
reconstructed by making use of the Depth-of-interaction capabil-
ities of the monolithic detector.
Methods: This system is characterised with regards to point and line
sensitivity for typical detector settings in current clinical PET systems.
In this study the effects of changing the axial length of the scanner
are studied in detail. Finally two options for imaging long objects
(above 1 m) with the same compact system are described.
Results: The system results in excellent spatial resolution at the sys-
tem level. The sensitivity gains for point sources and small objects
(brain type) are limited and are comparable to the increase in cost ofthe system. For longer objects (1-2m) the gains go up to a factor 15-
20 x. Scanners in the range of 70 cm-1m20 match well with the typ-
ical region of interest for PET imaging and have an optimal sensitivity
gain.
Conclusion: PET20.0 combines high and uniform spatial resolution at
the system with a major increase in sensitivity (close to a factor 20)
for total body imaging. This is accomplished by increasing the de-
tector material by a factor 3-4.
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Aim: Digital photon counting serves to improve both visual and
quantitative performance of PET/CT through advances in system sen-
sitivity, count statistics and time of flight timing resolution. Fitting
this data to a normalization curve such as with EARL requires a
reconstruction protocol secondary to the default high definition
protocol. We validated a vendor suggested EARL-compliant protocol
for clinical data sets acquired with digital photon counting PET via
intra-individual comparison to images acquired on a conventional
system.
Methods: 26 patients underwent PET/CT imaging on a conventional
system (Philips Gemini TF 64, cPET) approximately 75 minutes
post-injection of 480 MBq 18F-FDG and 55 minutes on a pre-
commercial release digital photon counting PET/CT system (Philips
Vereos, DPC dPET). Listmode data were reconstructed with default
settings: cPET – 4mm isometric voxel, 3 iterations, 33 subsets; DPC
dPET – 2mm isometric voxel, 3 iterations, 11 subsets, point spread
function correction and 4.1 mm Gaussian filter applied. DPC dPET
data were further reconstructed with an EARL-compliant protocol –
4mm isometric voxel, 3 iterations 13 subsets, 5mm Gaussian filter
which was previously validated with phantom data (1). Regions of
interest (ROIs) were placed over target lesions and in a variety of
background tissues for quantitative comparison.
Results: The average SUVmax of target lesions for default DPC dPET
reconstructions was 9.74. The cPET data presented a substantially
lower average SUVmax at 6.47, as anticipated due to lower recovery
coefficients. The EARL dPET reconstruction revealed quantitative
values comparable to cPET with an average SUVmax of 6.49. The de-
crease was due to an increase in partial volume effects by use of a
smaller reconstruction matrix/larger voxel size as well as the smooth-
ing introduced by the use of a Gaussian filter alone. In background
tissues, the SUVmean varied by less than 5% among all reconstruc-
tion settings.
Conclusion: The EARL-compliant reconstruction of DPC dPET clinical
cases as applied to intra-individual comparison data lead to quantita-
tive results which match conventional EARL PET/CT values. It was
demonstrated and validated that while DPC dPET imaging has sub-
stantially improved recovery coefficients, secondary reconstructions
can be performed to enable comparable quantification with conven-
tional PET systems and existing databases or inclusion in clinical trials.
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Aim: The aim of this sub-study of a randomized clinical trial was
to evaluate the relationship of peak creatine kinase (CK) and
peak sensitive cardiac Troponin I (sc-TnI) levels with perfusion
defect and left ventricular ejection fraction (LVEF) by gated
single-photon emission computed tomography myocardial perfusion
imaging (SPECT-MPI) in patients with ST-elevation myocardial infarction
(STEMI) undergoing primary percutaneous coronary intervention (pPCI)
during the acute phase and one month later.
Methods: Patients who were admitted with STEMI within 8 hours
of symptom onset underwent gated SPECT-MPI acquisition
(SPECT-LDCT, Siemens Symbia T6, Erlangen) within 24 hours (time-
point (TP) 1) after pPCI and one month later (TP 2). The MPI SPECT data
were reconstructed and analyzed using 4DM-SPECT software. The in-
farct size was defined as percentage of the total left ventricular myo-
cardium (%LV). Serial CK (U/L) und sc-TnI (μg/L) levels were
evaluated at presentation and 2, 6, 12, 24 and 48 hours after
pPCI, respectively. Both, peak NT-proBNP (ng/L) values and LVEF
in ECHO were assessed during day 2 and 5 after admission.
Results: Twenty-four consecutive patients (mean age 60±12 years,
8 females) were included in this analysis. All patients had TIMI 3
flow in the culprit vessel after pPCI. In total 19 patients
underwent SPECT on TP1 and 17 on TP2. The median perfusion
defect was significantly larger on TP1 compared to TP2 (34%LV
(IQR 16-54) vs. 16%LV (IQR 4-22), p=0.008). We found significant
correlations for peak sc-TnI and peak CK levels with the perfusion
defect assessed on TP1 (r=0.5, p=0.031; r=0.51, p=0.026; respectively)
and on TP2 (r=0.88, p<0.001; r=0.92, p<0.001, respectively). Nt-proBNP
values did not significantly correlate with the perfusion defect on either
TP1 or TP2 (r=0.486, p=0.056; r=0.329, p=0.297), respectively. However,
we found good correlations for LVEF between ECHO and SPECT
assessment at TP1 and TP2 (r=0.7, p=0.005 and r=0.68, p=0.007).
Conclusion: The results of this pilot study demonstrate a significant
correlation between infarct size assessed by use of SPECT-MPI and
peak values of the more specific cardiac biomarkers CK and sc-TnI.
This correlation was much higher one month compared to 24 hours
after pPCI. LVEF calculated with SPECT-MPI showed good correlation
to echocardiography irrespective of the TP. However, Nt-proBNP, a
marker of left ventricular function, was not correlated with infarct size,
which might be explained by stunning of potentially vital myocardium.References
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Aim: Breast cancer resistance protein (Abcg2) is an ATP-binding
cassette transporter and expressed in the canalicular (bile-facing)
membrane of hepatocytes, where it promotes hepatobiliary excre-
tion of diverse drugs and their metabolites. Inter-individual vari-
ability in hepatic Abcg2 transport activity may affect the safety
and efficacy of drugs excreted via hepatic Abcg2 from the body.
We have shown before that the radiolabeled tyrosine kinase in-
hibitor [11C]erlotinib undergoes in mice Abcg2-mediated hepato-
biliary excretion, suggesting an utility to measure the transport
activity of Abcg2 in the liver [1]. Aim of this study was to investi-
gate if [11C]erlotinib PET is sensitive enough to measure a reduc-
tion of Abcg2 expression in the liver using a transgenic mouse
model, in which the epidermal growth factor receptor (EGFR) was
cell-type specifically deleted in hepatocytes of the liver leading to
a down-regulation of Abcg2.
Methods: Healthy male EGFRΔhep mice (lacking EGFR in hepatocytes
of the liver, n = 5) and EGFRfl/fl mice (having normal EGFR expres-
sion in hepatocytes of the liver, n = 6) underwent an MR scan
followed by a 90-min dynamic PET scan after intravenous injection of
[11C]erlotinib. Concentration-time curves were derived for different
organs from the co-registered PET/MR images and the area under
the curve (AUC) from 0-90 min was calculated. Integration plot ana-
lysis was used to estimate the rate constant for transfer of radioactiv-
ity from the liver via bile into the intestine (kbile). Abcg2 protein
expression levels in liver tissue collected at the end of PET imaging
were determined with Western blot analysis.
Results: Western blot analysis revealed a significant reduction (-65%) of
hepatic Abcg2 protein expression levels in EGFRΔhep mice relative to
EGFRfl/fl mice. Intestinal AUC and kbile values were significantly lower
in EGFRΔhep as compared with EGFRfl/fl mice (intestine AUC, EGFRfl/fl:
1,340 ± 368 %ID/g*min, EGFRΔhep: 866 ± 86 %ID/g*min; kbile, EGFRfl/
fl: 0.018 ± 0.003 min-1, EGFRΔhep: 0.006 ± 0.002 min-1).
Conclusion: Our findings suggest that [11C]erlotinib PET is suitable to
measure a reduction in Abcg2 expression in the liver. Thus, [11C]erloti-
nib PET may be used to study the influence of liver disease, genetic
polymorphisms or drugs on hepatic Abcg2 transport activity.
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EJNMMI Research 2018, 8(Suppl 1):5 Page 7 of 12Aim: Portal neoplastic thrombus, present in 6.5%-44% of patients
with HCC, represents an important determinant of tumor staging
and prognosis and influences treatment selection.HCC invasion
into the portal vein renders a patient unsuitable for aggressive
treatment such as surgical resection, liver transplantation or
chemoembolization, due the high incidence of tumor recurrence.
The standard for characterizing portal vein thrombus is histopath-
ologic examination; in clinical practice others diagnostic imaging,
clinical and laboratory findings are often utilized for discrimin-
ation. We report a case of a 63 yrs male affected by HBV
cirrhosis and biopsy-proven multifocal HCC treated ten months
with Sorafenib.He showed a good response to the disappearance
of liver lesion and reduction of AFP value but the CT found a
portal thrombus suspected as neoplastic that would make the
patient unsuitable to the programmed liver transplantation.Diag-
nostic imaging as US, enhanced US and CT were not diagnostic.
No MRI was performed for the presence of foreign metallic bullet.
The patient was referred to 18F-FDG PET/CT for an accurate
differentiation of bland from neoplastic thrombus, basing on the
data published and considering the presence of a highly meta-
bolic pattern in malignant vein thrombosis.
Methods: Data acquisitions by an integrated PET/CT system (Philips
Gemini XLC) were performed within 60 min after 216 MBq of 18F-
FDG. A late liver image was registered.
Results: The 18F-FDG PET/CT showed a high uptake in the main
portal vein (SUV max 3.97) which increased in the late acquisi-
tion.Liver SUV was 2.45 and aortic SUV was 1.78. It is reported
that in PET/CT thrombi were considered malignant if the SUV is
greater than normal liver and/or the uptake is greater than that
of the descending aorta in the same axial slice with an optimal
cutoff value of SUV max 2.3-3.6. In our case the SUV value was
consistent with malignant vein thrombosis. Considering that
shrinkage of the thrombus and/or recanalization of the vessels
was a definitive evidence of the benign nature of the thrombosis,
the patient was followed-up monthly by US, CT and AFP value.
After four months the enhanced CT showed an enlargement of the
thrombus and parenchymal infiltration consistent with malignancy.
Conclusion: 18F-FDG PET/CT may be helpful in discriminating
between benign and malignant portal vein thrombi. Patients may
benefit from 18F-FDG PET/CT when portal vein thrombi cannot be di-
agnosed exactly by US, CT or when MRI isn’t feasible.
Consent to publish: Consent to publish was obtained from the
patient involved in this study
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This abstract is not included here as it has already been
published [1].
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Aim: The aim of this article is to find out how the attenuation correc-
tion in the case of the SPECT/CT imaging influences the quality of
the image, and also the effect of different acquisition time.
Methods: The Phantom NEMA IEC BodyPhantom was filled with the
isotope technetium-99m. Eight images were captured, each with a
different ratio of the specific activity between the phantom back-
ground and the spheres and also different acquisition time. The im-
ages were reconstructed in the program called Oasis by three
different reconstructions: the filtered back projection, the non-
corrected iterative reconstruction, and with the attenuation correc-
tion using the CT. The number of counts in the background and in
all six spheres was measured. This was followed by the comparison
of the contrast in images that were reconstructed using different
methods. A descriptive statistic and repeated ANOVA measure were
conducted. The Wilcoxon signed-rank test was carried out in Matlab.
Results: On the images that were processed by the filtered back
projection or the iterative reconstruction, the background is not homo-
geneous. On the images that were corrected using the CT, the number
of counts is evenly spread across the entire background of the phan-
tom, thus making the background homogeneous. The statistical ana-
lysis showed that p < 0.001, meaning that, statistically, contrast is
typically divergent among the different methods of reconstruction.
Conclusion: It was discovered that the increase in the number of
counts, and consequently the image contrast, is proportional to the size
of the sphere, and to the increased ratio of activity between the back-
ground and the sphere with all three types of reconstruction. The CT-
AC images have the best contrast; images with iterative reconstruction
are second best; images processed by the filtered back projection are
third. The images reconstructed with the CT-AC have the least negative
contrast, while the negative contrast in the images with iterative recon-
struction and FBP images is far more prominent. Also increased im-
aging time results in increased count number and better image quality.
Because the CT-AC images are of better quality than the non-corrected
images, it is recommended that the CT-AC be used for all tests; how-
ever due to the removal of artefacts caused by attenuation correction,
it is also important to examine the non-corrected images every time.
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Aim: Digital photon counting allows for higher definition image re-
construction than on conventional PET systems due to increased sys-
tem sensitivity, time of flight timing resolution, and count densities
(1). For neurologic applications, these improvements may greatly in-
crease the utility and accuracy of PET imaging. We validated and
EJNMMI Research 2018, 8(Suppl 1):5 Page 8 of 12optimized high definition image reconstruction methodologies using
the Hoffman brain phantom.
Methods: A Hoffman brain phantom was filled with 52 MBq 18F-FDG
and imaged on a pre-commercial release digital photon counting
PET/CT (Philips Vereos). Five minute acquisitions were repeated over
several runs using the dedicated brain 256 mm field of view (FOV)
and the whole body 576 mm FOV. Listmode data from each acquisi-
tion was reconstructed using the high definition (HD) 2x2x2 mm
voxel matrix. Reconstructions were performed with 3 iterations and a
range of subsets, 21, 17, 13, and 9. Additionally, the use of system
point spread function (PSF) correction and/or a Gaussian filter were
enabled. Regions of interest (ROIs) were placed in 10 unique regions
of the phantom for quantitative assessment. Blinded reader reviews
were performed to assess image quality.
Results: We found that the optimal reconstruction settings for each
FOV were distinct. For the 576 mm FOV the use of PSF alone, no
Gaussian filter, gave the most accurate quantitative results. The
addition of the Gaussian filter resulted in underestimation of activity
concentrations. The average recovery coefficients (RCs) of all ROIs
were very similar among reconstructions with different numbers of
subsets. The average RCs were 0.97, 0.95, 0.94, and 0.92 for the 21,
17, 13, and 9 subsets reconstructions, respectively. Blinded review
conveyed that the 13 subset images were most preferable with
regard to contrast and image noise. Thus the HD reconstruction with
PSF only using 3 iterations and 13 subsets was optimal for the whole
body FOV acquisitions. For the 256 mm FOV a Gaussian filter was
used in reconstruction as the PSF alone lead to overestimation of ac-
tivity concentrations. As with the whole body FOV, each subset set-
ting gave similar quantitative results, average RCs were 1.02, 1.01,
0.98, and 0.95 for the 21, 17, 13, and 9 subset reconstructions. Image
review again showed that fewer subsets were preferred, with the 9
subset reconstruction now being most ideal. For acquisitions with
the dedicated brain FOV, HD reconstruction with both PSF correction
and a Gaussian filter using 3 iterations with 9 subsets is optimal for
imaging with FDG.
Conclusion: Optimization of Neuro-PET reconstruction settings re-
vealed that these setting must be tailored to acquisition characteris-
tics, namely the chosen field of view. Phantom validation
demonstrated that high quantitative accuracy and excellent image
quality is readily achieved for neurologic imaging on next-generation
digital PET systems when using either a dedicated brain field of view
or the wider whole body field of view.
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Aim: The potential dose-limiting toxicity - especially when using
alpha-emitters like Ac-225- or Bi-213, remains an unresolved issue in
PSMA radioligand therapy (PRLT) of metastatic castration-resistant
prostate cancer (mCRPC) due to the normal biodistribution of PSMA-
radioligands in the salivary as well as in the lacrimal glands. Experi-
ence from over decades in external beam radiotherapy (EBRT) of the
head and neck region demonstrates that severe xerostomia could
become a life-quality-limiting factor. Since recent studies suggest a
more PSMA-independent uptake in the salivary and lacrimal glands(1), suppressing the gland metabolism appears to be a promising
method to achieve a lower uptake. Because of its safety and feasibil-
ity, injection of botulinum toxin into the salivary glands is commonly
used to treat severe sialorrhoea (even in children) and has already
been investigated as a potential radioprotective agent in EBRT (2).
Methods: A 63-year-old patient with mCRPC received multifocal
ultrasound-guided injections of botulinum toxin A, totally 80 units,
into his right parotid gland after a detailed informed consent. A
dynamic salivary gland scintigraphy (SGS) using Tc-99m pertech-
netate was performed before and after 70 h. At 45 days p.i., SGS
as well as Ga-68-PSMA-PET/CT were performed. Standardized up-
take values (SUV) of the right and left parotid glands were com-
pared to the baseline PET/CT study. The patient underwent
regular clinical follow up.
Results: Ga-68-PSMA-PET/CT performed 45 days after the botulinum
toxin injection showed a heterogeneous, but highly significant reduc-
tion of the radioligand uptake by up to 60 % (SUVmean) in the
injected right-sided parotid gland as compared to the left one. There
was a drop of the SUVmean in the right parotid gland by up to 64
%, whereas no significant change in uptake of the left parotid gland
was noted, when compared to the baseline PET/CT. The SGS also re-
vealed a distinct decline in the peak uptake of Tc-99m pertechnetate
in the injected parotid gland. The patient didn’t report any adverse
effects of the injections throughout the follow-up period of now up
to 2 months.
Conclusion: Intraparenchymal botulinum toxin injection impressively
decreases the uptake of PSMA radioligands in the salivary glands.
Therefore this approach (named 4B protection), which is described
here for the very first time and was pioneered by our group, could
be a significant breakthrough for salivary gland protection under
PSMA radioligand therapy.
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Aim: 99mTc-dimercaptosuccinic acid (DMSA) is an agent used for the
diagnosis and follow-up of renal scarring in children with ureteral re-
flux detecting scars and calculating the differential renal function
(DRF). DMSA has some disadvantages such as relatively higher radi-
ation dose and time consumption. Recently a new radiopharmaceuti-
cal Tc-99m-ethylenedicysteine (EC) has been developed for dynamic
scintigraphy and to measure renal function as an alternative to OIH
and Tc-99m-MAG3, with comparable characteristics. EC provides
high-quality images and low radiation dose. The purpose of this
study was to evaluate the effectiveness of EC scan compared with
DMSA in the detection of cortical lesions and DRF in order to per-
form only one scan with the advantage in terms of economy and
health care.
Methods: 20 children 0.2-2 years with ureteral reflux (III and IV) were
studied with DMSA and EC performed within 20-45 days. DMSA was
acquired 3-4 hours after i.v. injection (EAMN paediatric guidelines)
with 8 views (A/P, OP, PA and LL) by Philips Bright View XCT, LEHR
collimator, 256 matrix, 300 kcounts/view. EC was performed with
EJNMMI Research 2018, 8(Suppl 1):5 Page 9 of 12both detectors using the same equipment and recording dynamic
anterior/posterior images after bolus in a 64 matrix for 30 minutes.
First 180sec. images were summed in statics images in AP views.
Perirenal ROI’s were drawn automatically for uptake and background
and DRF was calculated. All images were also evaluated visually to
define parenchymal abnormalities. All patients underwent to external
dose rate measurements to evaluate the total decay constant (phys-
ical + biological).
Results: EC provided high-quality images even in newborns with a
low/negligible extra-renal clearance, low liver and intestinal activity
and high kidney-to-background ratio similar to DMSA, good delinea-
tion of the kidneys and detection of renal scars. DFR calculated and
compared for both agents showed a close correlation (r =0.979) be-
tween values obtained by the two different methods.The qualitative
analysis from DMSA and EC revealed 22 and 18 focal defects respect-
ively; four defects were not detected on EC summed image (22,3%)
possibly because the only A/P views, the lower counts and the
higher pixel size of dynamic acquisition.
Conclusion: DMSA-scan is the gold standard test for parenchymal
abnormalities and for the DRF. Ours preliminary results show that
EC images provide an accurate DRF calculation and detection of
scars in children with reflux. The absorbed radiation dose for EC
is lower than DMSA and represents an advantage in pediatrics.
Further studies are needed to determine if EC scans could be
used alone to assess cortical lesions and DRF in selected cases.
More cases are necessary to obtain a more accurate dosimetric
evaluation.
For the study, the approval of the local ethics committee was not ne-
cessary as both the radiopharmaceuticals, (Tc 99m L-ethylenedicys-
teine and s Tc 99m DMSa) are regularly registered for diagnostic use
in Italy. In addition, the patients used in the evaluation were chosen
from all those who performed the diagnostic test for clinical reasons
and requested from them reference specialist urologist.
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Aim: Generator costs are expected to rise significantly in the next few
years. This is due to issues around reactor closures and future supplies
being based on full cost recovery. Optimising the regular supply of
Mo99 generators is almost impossible to do by trial and error, particu-
larly for larger radiopharmacies getting two generators a week. Even
single generator use departments face problems since all the manufac-
turers have different delivery schedules and reference activities. I devel-
oped an EXCEL program 6 years ago which analysed all generators on
the UK market to match a departments requirements. This program
has had to be fully re-written for various factors described.
Methods: The generator range on the UK/EC market has significantly
expanded. In 2012 there were N = 112 different generators available
(from 3 manufacturers), but in 2017 there are now N = 303 different
generators,(from 4 manufacturers).. When both single generator and
2 generator usage is considered the number of possible options of
generator supply are [N*(N-1)]/2+2N. So the number of combinations
has risen from 6,440 to 46,359. The old program could not accommo-
date this number of generators. Also, the calculation algorithms of
the old program with this increase in numbers would take over
40minutes.
Results: The program has been completely rewritten, with the
following -
 Manufacturers’ generators can occupy separate worksheets.
 These individual worksheets are now separately selectable
(included or excluded) Calculation of each generator Tc99m activity is automatic (this
significantly aids data entry)
 Generators are pre-populated for major manufacturers so only
the local costs are entered.
 7day or 14day generator use is user selectable.
 Results are sorted in order of increasing cost, so usually only
the first batch of results need to be reviewed.
However the major change is the processing algorithm, which now
takes 840,000 combinations and take only 6seconds.
Conclusion: The program will be described (and possibly presented).
It is impossible to maximise the supply using trial and error, particu-
larly for 2 generators a week, and there is a potential for cost savings
to be made from optimising the generator supply.
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Aim: The increase in incidence of thyroid cancer during the last
decades (about 2% of new cancer cases in Austria) without con-
comitant rise in mortality may reflect the growing detection of
indolent forms of thyroid cancer. Our aim was to analyze the cancer
statistics of our patients who underwent surgery in the time period of
2012-2016..
Methods: In the time period of 2012-2016 a total number of 636
patients (473 f, 166 m, age range 12-92y, median age 52 + 13,83y)
were sent after decision making in thyroid board, consisted of
nuclear medicine, surgery, pathology and ear-nose-throat (ENT)
specialists. All surgical specimens were examined at the department
for pathology in our hospital. Preoperative examination included
sonography of thyroid gland and lymphatic tissue, scintigraphy, fine
needle aspiration cytology in case of clinically suspect nodules,
otolaryngological examination and laboratory analysis including
Calcitonin if nodules were present.
Results: The temporal analysis of our patients in the time period of
2012-2016 revealed 135 cancer cases with following histological
diagnosis:
54 PTC, 13FTC, 7 MTC, 1 anaplastic cancer, 1 metastasis of a renal
cancer. 59 were staged as pT1a (6 pT1a(m) > 5mm, 1 tall-cell variant
> 5mm with lymph vessel involvement and 2 with lymph node me-
tastasis) and 26 patients with > pT1a had LN metastasis, and 2
showed distant metastasis at the time of diagnosis.
The annual incidence (%) of thyroid cancer (TC) was as in the follow-
ing Table 2.
Conclusion: We observed a high cancer incidence of about 21%
in our patients compared to the low rate of 2% thyroid cancer
patients of new cancer cases in Austria. To our opinion a
stringent patient selection in the interdisciplinary preoperative
management of thyroid patients according to guidelines is the
decisive factor for this high rate of thyroid cancer in our
patients.
References
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Table 2 (abstract PP10). See text for description
Year (f) (m) Total
2012 17 6 14
2013 20 17 19
2014 18 31 21
2015 22 9 19
2016 31 27 30
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Aim: We aimed to study the validity of six published ultrasound
criteria for risk stratification of thyroid nodules in the former severely
iodine deficient population of Austria.
Methods: Retrospective, single centre, observer blinded study design.
All patients with a history of thyroidectomy due to nodules seen in
the centre between 2004 and 2014 with preoperative in-house son-
ography and documented postoperative histology were analyzed
(n=195). A board of five experienced thyroidologists evaluated the
images of 45 papillary carcinomas, 8 follicular carcinomas, and 142
benign nodules regarding the following criteria: mild hypoechogeni-
city, marked hypoechogenicity, microlobulated or irregular margins,
microcalcifications, taller than wide shape, missing thin halo.
Results: All criteria but mild hypoechogenicity were significantly
more frequent in thyroid cancer than in benign nodules. The number
of positive criteria was significantly higher in cancer (2.79±1.35) than
in benign nodules (1.73±1.18; p<0.001). Thus, with a cut-off of two or
more positive criteria, a sensitivity of 85% and a specificity of 45%
were reached to predict malignancy in this sample of thyroid nod-
ules. As expected, the findings were even more pronounced in
papillary cancer only (2.98±1.32 vs. 1.73±1.18, p<0.001). The six ultra-
sound criteria could not identify follicular cancer.
Conclusion: Our findings support the recently published EU-TIRADS
score. Apart from mild hypoechogenicity, the analyzed ultrasound
criteria can be applied for risk stratification of thyroid nodules in the
previously severely iodine deficient population of Austria.
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Aim: P-glycoprotein (Pgp), a membrane transporter expressed at the
blood-brain barrier (BBB), may contribute to clearance of beta-
amyloid (Aß) from the brain [1, 2]. Positron emission tomography
(PET) with the Pgp substrate (R)-[11C]verapamil ([11C]VPM) has
shown that cerebral Pgp function is reduced in Alzheimer’s disease
(AD) patients and during healthy ageing [3, 4]. Transgenic mouse
models are commonly used in AD research. It is currently not knownif [11C]VPM PET possesses adequate sensitivity to detect a moderate
reduction in Pgp function at the BBB as it occurs in AD mouse
models. In the present study, we employed a novel partial Pgp inhib-
ition protocol using tariquidar [4] to assess Pgp function with
[11C]VPM PET in one commonly employed AD mouse model
(APPPS1 mice) and in age-matched wild-type mice.
Methods: Female C57BL/6N wild-type and APPPS1 mice aged 50
days and 200 days underwent dynamic [11C]VPM PET scans after
pre-treatment with vehicle or the Pgp inhibitor tariquidar at a dose
of 4 mg/kg leading to partial Pgp inhibition at the BBB (n = 4 - 6). In
addition, heterozygous Pgp knockout mice (Abcb1a/b(+/-)) were
studied as a model of 50% reduction in Pgp density at the BBB. At
the end of the PET scan a venous blood sample was collected by
retro-orbital puncture. Brain uptake of [11C]VPM was expressed
as the brain-to-plasma ratio of radioactivity in the last PET
frame (Kp,brain). Plasma was analyzed by radio-TLC for radiola-
beled metabolites of [11C]VPM. Immunohistochemical (IHC)
staining was performed to visualize the spatial distribution of
Pgp in the brain.
Results: In PET scans without Pgp inhibition, Kp,brain values of
[11C]VPM were not significantly different between all mouse groups.
Administration of tariquidar led to increases in Kp,brain values, which
differed among groups with the following rank order: wild-type 50
days: +23 ± 10%, APPPS1 50 days: +31 ± 14%, wild-type 200
days: +31 ± 11%, APPPS1 200 days: +39 ± 23%, Abcb1a/b(+/-): +59 ±
6%. After tariquidar administration, Kp,brain values were significantly
higher in wild-type mice aged 200 days than 50 days (1.02 ± 0.10 vs.
0.90 ± 0.11, p = 0.04, Student’s t-test). In addition, higher Kp,brain
values were detected in APPPS1 mice aged 50 days compared to
wild-type mice aged 50 days (1.09 ± 0.07 vs. 0.90 ± 0.11, p = 0.01). In
Abcb1a/b(+/-) mice, Kp,brain values after tariquidar administration
(1.32 ± 0.11) were significantly higher than in wild-type and
APPPS1 mice from both age groups. No differences in the per-
centage of radiolabeled metabolites of [11C]VPM in plasma were
observed between wild-type and APPPS1 mice. IHC analysis of
brain slices confirmed reduced Pgp expression in brain capillaries
of APPPS1 mice as compared with wild-type mice.
Conclusion: Our data confirm previous findings that [11C]VPM PET
without inhibitor administration lacks the sensitivity to detect moder-
ate changes in Pgp function at the BBB [4]. We obtained evidence
that [11C]VPM PET in combination with partial Pgp inhibition with
tariquidar can be used to detect age- and AD-related reductions in
Pgp function at the BBB of mice. The employed PET protocol may
prove useful in future studies evaluating different therapeutic ap-
proaches to restore Pgp function at the BBB.
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EJNMMI Research 2018, 8(Suppl 1):5 Page 11 of 12Aim: 18F-FDG PET/CT has been described as a helpful diagnostic tool
in FUO (fever of unknown origin) when other radiological or labora-
tory methods fail to explain the fever origin. We present preliminary
results from a large single-center retrospective study on the diagnos-
tic value of 18F-FDG PET/CT in FUO.
Methods: We included 143 patients (65 male 45%; 78 female 55%)
who presented with a history of FUO. Microbiological and histo-
logical findings, patient follow-up and further treatment were retro-
spectively correlated to PET/CT findings.
Results: In 109 (76.2%) cases, PET/CT findings correlated positively
with the final diagnosis, while in 17 (11.9%) cases the PET/CT findings
only partially correlated with the final diagnosis. In 17 (11.9%) cases
PET/CT findings were false-positive. In 56 (39.2%) cases PET/CT
showed no focus.
In in 43 cases (30.1%) fever was caused by various infectious diseases;
in 22 cases (15.4%) fever was a sign of malignoma; in 21 cases (14.7%),
fever was caused by autoimmune or rheumatic diseases; in 6 cases
(4.2%) miscellanceous diseases were reported. In 28 cases (19.6%) no
underlying disease could be found.
In 23 (16.1%) cases a plausible cause for fever was previously known,
PET/CT was performed to outrule another infectious or malignant source,
in this cases PET/CT showed no other focus or signs of malignancy.
Conclusion: 18F-FDG PET/CT is the gold standard in FUO diagnostics
in nuclear medicine, particularly when other radiological and labora-
tory methods fail to provide an explanation for FUO. Our study
delivers important data for the use of 18F-FDG-PET/CT in FUO, since
there is still a lack of large studies to support this hypothesis.
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Aim: For patients on chronic hemodialysis (HD) treatment, vascular
access is required. Insertion of arteriovenous graft (AVG) is indicated
in patients with a failed arteriovenous fistula. The aim of this study
was to evaluate 18F-FDG PET/CT in detection of early AVG infections.
Early treatment of AVG infection is important, because an advanced
prosthetic infection usually leads to removal of the prosthesis.
Methods: A total of 51 AVGs was evaluated. One-year monitoring
was completed in 30 AVGs. 18F-FDG PET/CT was performed at inter-
vals of 10, 20–30, and 40–50 weeks after AVG insertion. Increased
accumulation of FDG and WBC in the prosthesis was classified as
focal or diffuse. An agreement between the 18F-FDG PET/CT and“reference” parameters (clinical local status, CRP, and microbiological
evaluation of a swab sampled from the HD cannula immediately
after the HD procedure) was evaluated using the Gwet’s coefficient
AC1 and McNemar test for symmetry.
Results: At 10 weeks since AVG implantation the AC1 values were: focal
18F-FDG accumulation - clinical status AC1 0.693, CRP AC1 0.605, can-
nula microbiology AC1 0.518; focal and diffuse 18F-FDG accumulation -
clinical status AC1 0.617, CRP AC1 0.695 (but McNemar 0.039), cannula
microbiology AC1 0.628; diffuse 18F-FDG accumulation - clinical status
AC1 0.079, CRP AC1 0.167, cannula microbiology AC1 0.255. At 20 to 30
weeks after AVG implantation: focal 18F-FDG accumulation - clinical sta-
tus AC1 0.656, CRP AC1 0.570, cannula microbiology AC1 0.409; focal
and diffuse 18F-FDG accumulation - clinical status AC1 0.596, CRP AC1
0.669, cannula microbiology AC1 0.518 (McNemar 0.012),; diffuse 18F-
FDG accumulation - clinical status AC1 0.073 (McNemar 0.041), CRP
AC1 0.166, (McNemar 0.031), microbiology AC1 0.076. Between 40 and
50 weeks since AVG implantation: focal 18F-FDG accumulation - clinical
status AC1 0.524 (McNemar 0.039), CRP AC1 0.456, cannula microbiol-
ogy AC1 0.569; focal and diffuse 18F-FDG accumulation - clinical status
AC1 0.673, CRP AC1 0.710, cannula microbiology AC1 0.720; diffuse
18F-FDG accumulation - clinical status AC1 0.347 (McNemar 0.039), CRP
AC1 0.385, cannula microbiology AC1 0.371.
Conclusion: The study results show that focal accumulation of 18F-
FDG (in combination with diffuse uptake or solely) can be considered
as a sign of early AVG infection in HD patients. This fact is consistent
with the results of similar 18F-FDG PET/CT studies concerning infec-
tions of common AVG grafts (1, 2). 18F-FDG PET/CT can serve as a
supportive parameter indicating the need for antibiotic therapy in
early infection of AVG in HD patients.
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Aim: Zirconium-89 has gained great interest for PET, when imaging at
late time points is required. Desferrioxamine B (DFO), is mostly used for
this radionuclide as bifunctional chelator (BFC) and we recently reported
on fusarinine C (FSC) with similar zirconium-89 complexing properties but
potentially higher stability related to its cyclic structure. This study reports
on the comparison of FSC and DFO as BFCs for 89Zr labelling of the affi-
body ZEGFR:2377 targeting Epidermal Growth Factor Receptors (EGFR).
Methods: FSC-ZEGFR:2377 and DFO-ZEGFR:2377 were evaluated re-
garding labeling, in vitro stability, specificity, cell uptake, receptor af-
finity, biodistribution and microPET-CT imaging.
Results: Both conjugates showed increased labelling yields at elevated
temperature (85°C). Both conjugates revealed remarkable specificity, af-
finity and slow cell-line dependent internalisation. Labeling at 85°C
showed comparable results in A431 tumor xenografted mice with
EJNMMI Research 2018, 8(Suppl 1):5 Page 12 of 12minor differences regarding blood clearance, tumor and liver uptake
but clear improvement as compared to 89Zr-DFO-ZEGFR:2377, labeled
at room temperature, which was confirmed by MicroPET-CT imaging.
Conclusion: We were able to show that FSC is a suitable alternative to
DFO for labeling of biomolecules with zirconium-89. Furthermore our
findings indicate that 89Zr- labeling of DFO conjugates at higher
temperature reduces off-chelate binding leading to significantly
improved tumor-to-organ ratios and therefore enhancing image contrast.
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Aim: Aspergillus fumigatus produces the siderphore triacetylfusari-
nine C (TAFC) for iron acquisition and is essential for its virulence,
therefore a specific marker for invasive aspergillosis. [68Ga]TAFCexhibited excellent targeting properties in A. fumigatus infection
model. We aimed to modify TAFC to investigate the influence of in-
troduced substitutes on preservation of TAFC characteristics in vitro
and in vivo.
Methods: Various TAFC modifications with various substitution (different
carbon chain length acyl compounds as well as charge substitutents) were
prepared and labelled with 68Ga. Stability, log P and Protein binding was
assessed. Uptake and growth studies in Aspergillus species expressing the
specific TAFC Transporter (MirB) were performed. Normal biodistribution
and μPET Imaging of selected compounds was performed.
Results: In vitro uptake studies using A. fumigatus showed the recogni-
tion of MirB to monosubstituted TAFC whereas uptake assays of MirB-
possesing- and wildtype-A. terreus confirmed the specificity to TAFC of
MirB transporter. Llipophilicities as expressed in logD were -0.38 to -3.80.
One selected compound, [68Ga]DABuFC displayed low protein binding
and was stable in PBS and serum and revealed comparable biodistribu-
tion behaviors and image contrast by PET/CT compared to [68Ga]TAFC.
Conclusion: Our studies show the possibility to modify TAFC without
losing its properties and recognition of MirB. Introducing functional-
ities such as fluorescent dyes or anti-infection moieties opens new
ways for theranostics of infection diseases.
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